When investing in research and development (R&D), institutions must decide whether to take a top-down approach — soliciting a particular technology — or a bottom-up approach in which innovators suggest [...]
This staff report describes the actions of Celgene Corporation and Bristol Myers Squibb Company in repeatedly raising the price of Revlimid, a critical drug to treat multiple myeloma and other [...]
Big Pharma’s innovation argument just does not stand up to scrutiny. We can’t allow drug corporations to continue to hide behind their threat that if we do anything to curb [...]
The age-old clash between celebrities and paparazzi has reached a new high. With the trend moving towards the monetization of social media, evolution in mobile camera technology, and lighting-fast sharing [...]
Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs [...]
Technical progress increasingly relies on the use of scientific knowledge. But if much of this knowledge is in the public domain, can it be a source of private value? We [...]
One of the key recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine is to take a societal perspective when evaluating new technologies—including measuring the productivity benefits of [...]
Knowledge of how science is consumed in public domains is essential for a deeper understanding of the role of science in human society. While science is heavily supported by public [...]
When judges change the legal rules governing patents, those changes are always retroactive. That is, they apply equally to patents that have already been granted and patents that do not [...]
As the U.S. patent system has weakened, venture capital investment shifted away from patentintensive industries. We supplemented our exhaustive review of 14 years of data tracking VC investment by talking [...]